In this podcast dr. Efstathios Kastritis shares the primary results from the ANDROMEDA study examining subcutaneous daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light chain amyloidosis.
Top
